Here's what I know... On December 2nd, Todos Medical

New Post Public Reply Private Reply Replies (0) Message Board
redspeed
368
Here's what I know...

On December 2nd, Todos Medical Announces all 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation

In that PR on Dec. 2nd, the Company said they expect the data analysis to be completed in December 2021

They didn't say it will. Too many things outside their control. They said they expect. Unfortunately covid gets in the way.

For those that may ask, why does any company give any dates since nothing is ever certain? Well, if they said, we are going to finish sometime in the future, it wouldn't go well and/or twitter trolls fingers would start bleeding. If I was Gerald, I would ignore them and not waste a second. You have a combination of new twitter accounts because the others got canned, first stock buyers and people way, way, way over their skis.

They also didn't say they would announce results, they said they expect the data analysis to be completed. No different than me telling my wife I 'expect' to do well in a stock and she hears 'will'.

On Jan 10th. Gerald said "the biomarker data is now being run and put into the electronic data capture system before the data can be locked for statistical analysis. Should be done in the next few days then QC before formal data lock so the analysis will be very short"

I was thinking, thank goodness they are using the electronic system instead of punch cards. In biotech, they still use old terminology.

Does someone look at the data before the data lock? idk, what are the rules?

Does someone look at the biomarker data after it run? idk, what are the rules?

I would think the most important part is to lock in your end points before looking at the data. When were those endpoints locked? Does that happen before the data lock? I would think so, but what do I know.

There are not a lot of end points in this trial nor many biomarkers. Analysis, as Gerald said, should be quick. Me thinks an hour.

Coincidence Gerald was on Fox on Jan. 11th.

Next day Jan 12th, they announced they will present the results on January 27th
Why would you pick a date in about two weeks in this uncertain world unless you already have a pretty, pretty, pretty good feeling?

In that PR they said "The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial."
Week ending 17th would be Sunday Jan. 23, so Gerald updates shareholder Monday instead.

Here's what we know...

3cl protease inhibitors work. If you have doubts, give Pfizer a call.

Tollovir is a 3cl protease inhibitor

It worked great in the observational trial

Now did the 11 people get better, faster, stronger and not die because they willed it as they thought they were getting a miracle drug?

I'd find that hard to think that would be possible, but anything is possible. My money is on, Tollovir works. So far, those that I know with a bottle of Tollovid, haven't contracted Covid or if they did, it never reared it's ugly head.

The big question for me is, does it prevent the cytokine storm. Well, for those 11 it appeared it did. Feel bad for the people that didn't get Tollovir including the 5 that died.

Did Todos just get plain lucky, I doubt it. You would think there were others on the way to the hospital or in the hospital where someone tried Tollovid or Tollovir. Not like Tollovid needs a prescription which makes it very compelling.

So what happens if the anti-cytokine doesn't work? Then Tollovid makes a dam good product for outpatients, mild, moderate.

I posted on the Todos board, Zicam sold for 1/2 billion in 2020 and that is easily replicated too.

What's funny about Tollovid. I don't even have to convince people to buy it, especially if they were exposed to Covid, have a sniffle, scratchy throat, etc. I really thought I would, but it's usually a 1 minute conversation.

Now back to my NFL arm chair quarterbacking


Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NYSE Reflects on 9/11: Honoring Lives and Legacy

Updated Category News Views 7

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 4

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Sustainability Investments: $17 Trillion Wager Faces Divergence

Updated Category News Views 4

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Continue Reading
Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 8

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 11

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
2026 Buy-Side Index Reveals State Market Variance

Updated Category News Views 6

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 4

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 5

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
High-Grade Copper Spurs Optimism for PolarX in Alaska

Updated Category News Views 4

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 14

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading

Top 5 Most Recently Viewed Articles

Cartography Biosciences Expands Clinical Advisory Board

Updated Category News Views 114

Cartography Biosciences Expands Its Clinical Advisory Board Cartography Biosciences, an innovative oncology company with a focus on antibody therapeutics, has taken a significant step towards enhancing its capabilities by appointing four prominent industry and academic leaders to its Clinical Advisory Board (CAB). This strategic initiative aims to augment the company's...

Continue Reading
Strategic Investment of $58 Million to Accelerate BNB Vision

Updated Category News Views 249

Applied DNA Sciences Engages in Strategic Fundraising Applied DNA Sciences Inc. (NASDAQ: APDN) has embarked on an ambitious journey to secure a substantial commitment of up to $58 million. This funding is set to initiate their distinguished digital asset treasury strategy, focused on the integration of BNB, which is the native cryptocurrency of the esteemed Binance...

Continue Reading
Zepp Health Launches Innovative Zepp App 9 for Users

Updated Category News Views 355

Zepp Health Introduces Zepp App 9 Zepp Health Corporation (NYSE: ZEPP) has unveiled its latest innovation, the Zepp App 9. This smart wearable application is designed to significantly enhance the health, wellness, and fitness tracking capabilities for users of Amazfit devices. The updated application brings a variety of exciting new features tailored to deliver a more...

Continue Reading
Navigating High-Yield Savings Accounts vs. Treasury Bills

Updated Category News Views 343

The Changing Landscape of Low-Risk Investments Not too long ago, low-risk investment options like Treasury bills were often seen as underperformers in the financial world. While Treasuries provided a secure place for savings, they didn't offer the attractive returns that savings accounts did. Recently, however, a notable shift has taken place as interest rates have risen,...

Continue Reading
Market Insights: Recent Trends in BellRing Brands Options

Updated Category News Views 219

Market Insights on BellRing Brands Options In the dynamic world of investment, it has been observed that financial giants are making noteworthy bearish moves concerning BellRing Brands Inc. Our in-depth analysis of recent options trading activity surrounding BellRing Brands (BRBR) has uncovered a pattern of unusual trades that cannot be ignored. Unpacking the Trading Data...

Continue Reading